CNS Pharmaceuticals Announces Adaptive Trial Design For Berubicin Phase 2 Clinical Trial To Be Submitted for FDA Review Nov 09, 2020 8:00am EST
CNS Pharmaceuticals Completes Manufacturing of Berubicin for Phase 2 Clinical Trial Oct 29, 2020 8:00am EDT
CNS Pharmaceuticals Completes U.S. Manufacturing of Berubicin for Phase 2 Clinical Trial Oct 20, 2020 8:00am EDT
CNS Pharmaceuticals Highlights New Balancing Act Segment on Glioblastoma Airing on Lifetime TV Oct 12, 2020 8:00am EDT
CNS Pharmaceuticals and Image Analysis Group Partner to Further the Development of Berubicin Sep 24, 2020 8:00am EDT
CNS Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Sep 17, 2020 8:00am EDT
CNS Pharmaceuticals to Present at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference Sep 11, 2020 8:00am EDT
